Improvement of immunogenic chemotherapy by STAT3 inhibition. Academic Article uri icon

Overview

abstract

  • The inhibition of STAT3 may exert cell-autonomous cytotoxic and cytostatic effects, yet may also stimulate anticancer immunosurveillance through the neutralization of immunosuppressive circuitries. In addition, STAT3 inhibition in cancer cells may stimulate the type 1 interferon response elicited by anthracyclines. This pathway results in an enhanced chemotherapy-associated anticancer immune response with improved therapeutic efficacy. Hence, combination therapies that include immunogenic cell death (ICD) inducers and STAT3 inhibitors can be envisaged.

publication date

  • September 11, 2015

Identity

PubMed Central ID

  • PMC4801443

Scopus Document Identifier

  • 84942888151

Digital Object Identifier (DOI)

  • 10.1158/0008-5472.CAN-15-1122

PubMed ID

  • 27057456

Additional Document Info

volume

  • 5

issue

  • 2